Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer

Bermekimab is a true human monoclonal antibody that targets interleukin-1alpa (IL-1α), an inflammation-mediating alarmin. IL-1 receptor antagonist (IL-1Ra) is a natural molecule that blocks IL-1α activity by occupying the IL-1 receptor. The effect of endogenous IL-1Ra levels on the effectiveness of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurzrock, Razelle, Hickish, Tamas, Wyrwicz, Lucjan, Saunders, Mark, Wu, Qian, Stecher, Michael, Mohanty, Prasant, Dinarello, Charles A., Simard, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350690/
https://www.ncbi.nlm.nih.gov/pubmed/30723583
http://dx.doi.org/10.1080/2162402X.2018.1551651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350690/
https://www.ncbi.nlm.nih.gov/pubmed/30723583
http://dx.doi.org/10.1080/2162402X.2018.1551651

Ejemplares similares